Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours

NCT04969835 is registered in ClinicalTrials.gov with Avacta Life Sciences Ltd as lead sponsor.

NCT NCT04969835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04969835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours
Lead sponsor
Avacta Life Sciences Ltd
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 16, 2021
Completion date
August 6, 2027
Enrollment
158 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian carcinoma, salivary gland tumor, soft tissue sarcoma, urothelial carcinoma